Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally C M Lau

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2023
The Value of Comprehensive Molecular Profiling in Early Stage Lung CancerSally C M Lau
Journal of Thoracic Disease|October 22, 2019
Hyperprogressive disease with immunotherapy: new directionsSally C M Lau, Natasha B Leighl
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLCSally C M Lau, Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?Sally C M Lau, Sai-Hong Ignatius Ou
Cancer Cell|October 21, 2022
Squamous cell lung cancer: Current landscape and future therapeutic optionsSally C M Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Drugs|May 10, 2019
Dacomitinib in the Management of Advanced Non-Small-Cell Lung CancerSally C M Lau, Ullas Batra, Tony S K Mok, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 25, 2023
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine NeoplasmsLynnette Fernandez-Cuesta, Alexandra Sexton-Oates, Leyla Bayat, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2020
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patientsJanice J N Li, Khizar Karim, Mike Sung, et al.
The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerDavid M Hwang, Tahani Albaqer, Rex C Santiago, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2023
The Value of Comprehensive Molecular Profiling in Early Stage Lung CancerSally C M Lau
Journal of Thoracic Disease|October 22, 2019
Hyperprogressive disease with immunotherapy: new directionsSally C M Lau, Natasha B Leighl
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLCSally C M Lau, Sai-Hong Ignatius Ou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?Sally C M Lau, Sai-Hong Ignatius Ou
Cancer Cell|October 21, 2022
Squamous cell lung cancer: Current landscape and future therapeutic optionsSally C M Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Drugs|May 10, 2019
Dacomitinib in the Management of Advanced Non-Small-Cell Lung CancerSally C M Lau, Ullas Batra, Tony S K Mok, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 25, 2023
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine NeoplasmsLynnette Fernandez-Cuesta, Alexandra Sexton-Oates, Leyla Bayat, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2020
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patientsJanice J N Li, Khizar Karim, Mike Sung, et al.
The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerDavid M Hwang, Tahani Albaqer, Rex C Santiago, et al.
Pageof 3